World's Best Scientists 2026 revealed!
Mitchell F. Brin

Mitchell F. Brin

D-Index & Metrics

Medicine

D-Index
92
Citations
33428
World Ranking
11250
National Ranking
29

Overview

Mitchell F. Brin is affiliated with Allergan (Ireland) in Ireland and has an extensive publication record in the field of medicine, particularly focusing on neurological disorders and treatments.

Their research primarily centers on the application and mechanism of botulinum toxin, with a significant emphasis on neurological implications and related therapeutic uses. The main scientific fields covered include medicine, with specific focus areas in neurology, psychiatry and mental health, physiology, dermatology, and cardiology and cardiovascular medicine.

Key topics explored in their work include:

  • Botulinum Toxin and Related Neurological Disorders
  • Migraine and Headache Studies
  • Neurological disorders and treatments
  • Facial Rejuvenation and Surgery Techniques
  • Pain Mechanisms and Treatments
  • Sympathectomy and Hyperhidrosis Treatments
  • Cardiac Arrhythmias and Treatments

Notable recent publications authored or co-authored by Mitchell F. Brin include:

  • Botox (onabotulinumtoxinA) mechanism of action, 2023, Medicine
  • Guidance for the diagnosis and treatment of hypolipidemia disorders, 2022, Journal of clinical lipidology
  • Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review, 2020, Headache The Journal of Head and Face Pain
  • The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial, 2020, EClinicalMedicine
  • A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine, 2020, Headache The Journal of Head and Face Pain

Mitchell F. Brin frequently publishes in the following venues:

  • Medicine
  • Toxicon
  • Cephalalgia
  • Neurology
  • Toxins

Collaborations form an integral part of their research activity. The scientist has frequently co-authored with:

  • Aubrey Manack Adams
  • Rami Burstein
  • Elisabeth Lee
  • Ron S. Broide
  • Amy Brideau-Andersen

Mitchell F. Brin's body of work reflects a consistent focus on advancing understanding of botulinum toxin usage in neurology, with significant attention to migraine, headache disorders, and related therapeutic applications, while also addressing broader topics within medicine and neurological health.

Best Publications

  • Consensus statement of the Movement Disorder Society on tremor

    Günther Deuschl;Peter Bain;Mitchell Brin

  • A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†

    C. Warren Olanow;Christopher G. Goetz;Jeffrey H. Kordower;A. Jon Stoessl

  • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

    W. Koller;C. W. Olanow;R. Rodnitzky;J. S. Fink

  • The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein

    Laurie J. Ozelius;Jeffrey W. Hewett;Curtis E. Page;Susan B. Bressman

  • THERAPEUTIC USES OF BOTULINUM TOXIN

    Joseph Jankovic;Mitchell F. Brin

  • OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

    David W. Dodick;Catherine C. Turkel;Ronald E. Degryse;Sheena K. Aurora

  • Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

    Brigitte Schurch;Marianne de Sèze;Pierre Denys;Emmanuel Chartier-Kastler

  • Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

    Mitchell F. Brin

  • Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

    Francisco Cruz;Sender Herschorn;Philip Aliotta;Mitchell Brin;Mitchell Brin

  • Idiopathic cervical dystonia: Clinical characteristics

    Jane Chan;Mitchell F. Brin;Stanley Fahn

  • Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.

    Mitchell F. Brin;Stanley Fahn;Carol Moskowitz;Andrzej Friedman

  • Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients

    Andrew Blitzer;Mitchell F. Brin;Celia F. Stewart;Celia F. Stewart

  • Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

    William J. Binder;Mitchell F. Brin;Andrew Blitzer;Larry D. Schoenrock

  • The DYT1 phenotype and guidelines for diagnostic testing

    Susan B Bressman;C Sabatti;Deborah Raymond;D de Leon

  • Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

    A. Brashear;M. F. Lew;D. D. Dykstra;C. L. Comella

  • Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis.

    P. Greene;U. Kang;S. Fahn;M. Brin

  • Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity

    David Ginsberg;Angelo Gousse;Veronique Keppenne;Karl-Dietrich Sievert

  • Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia).

    Andrew Blitzer;Mitchell F. Brin;Stanley Fahn;Robert E. Lovelace

  • Human gene for torsion dystonia located on chromosome 9q32-q34.

    Laurie Ozelius;Patricia L. Kramer;Carol B. Moskowitz;David J. Kwiatkowski

  • Statement on Use of Apolipoprotein E Testing for Alzheimer Disease

    Lindsay A. Farrer;Mitchell F. Brin;Louis Elsas;Alison Goate

Frequent Co-Authors

Stanley Fahn
Stanley Fahn Columbia University
William C. Koller
William C. Koller University of Miami
Laurie J. Ozelius
Laurie J. Ozelius Harvard University
Xandra O. Breakefield
Xandra O. Breakefield Harvard University
Andres M. Lozano
Andres M. Lozano University of Toronto
John G. Nutt
John G. Nutt Oregon Health & Science University
Patricia L. Kramer
Patricia L. Kramer Oregon Health & Science University
Andrew J. Lees
Andrew J. Lees University College London
Susan B. Bressman
Susan B. Bressman Mount Sinai Beth Israel
Neil Risch
Neil Risch University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring diverse routes in healthcare, a range of online degrees and accelerated career options are available. Many aspiring nurses are seeking rn to bsn programs without clinicals, which allow experienced RNs to advance their qualifications without additional on-site requirements. This can be a flexible solution for working professionals.

Those aiming for doctoral credentials can also benefit from online options. If speed is a main priority, the shortest post master's dnp program pathways can help nurses reach the highest clinical level in less time. For those concerned about research and writing, dnp programs without dissertation have become increasingly popular, offering a more practical, project-based approach.

Entry-level students can also find fast-paced opportunities, such as an accelerated lpn program. These programs make it possible to jumpstart a nursing career quickly while studying online. Each of these career pathways is designed to fit different goals and lifestyles, opening doors to advancement in the medical field.

Best Scientists Citing Mitchell F. Brin

Trending Scientists

Recently Published Articles